Ballard Power Systems (NASDAQ: BLDP) (TSX: BLDP) has purchased complete ownership of its European subsidiary from Dansk Industri Invest A/S for what it termed a “nominal value”. The subsidiary is now named Ballard Power Systems Europe A/S.

With that name change, the subsidiary will now use the Ballard brand, such as visual identity and logo, and will play an expanded role in supporting all of Ballard’s activities in Europe. The transaction will enable the company to not only acquire all the shares of the company, but also cancel the debt owed by the parent company to Dansk Industri. Prior to this, Ballard held 57% of the shares of the subsidiary, while Dansk Industri held the other 43%.

Ballard is a clean power company that specializes in fuel cell stack development (proton exchange membrane), fuel processing and systems integration. Ballard is considered one of the key vendors in the global fuel cell market. The company has announced that its fuel cells, branded as FCveloCity®, are in engines used in 80 buses internationally in Europe, China, the United States, Brazil, and India. Ballard is currently focused on expanding within the countries in which it is already operating, as well as adding to the list of countries using its fuel cell engines. Other transportation systems also use the technology, such as light rail.

The acquisition of the subsidiary closed on January 5, 2017. In a news release, Tony Guglielmin, CFO of Ballard Power Systems and chairman of Ballard Power Systems Europe A/S, said the company began the takeover process two years ago. “Europe is a critically important market for Ballard and we have taken important steps to strengthen our sales, engineering and service capabilities to support expected market growth,” he noted. About 50 employees work at the European subsidiary based in Hobro, Denmark. Ballard’s headquarters are located in Burnaby, British Columbia, in Canada.

Randy MacEwen, Ballard president and CEO, also said that the company achieved 10 million cumulative kilometers (6.2 million miles) worldwide with vehicles powered by its fuel cell motors. “We are moving beyond technical validation into commercial scaling at a time where market demand is at a breakthrough inflection point,” he said. “The cumulative learning by Ballard during our unparalleled field experience serves as a major competitive differentiator.” The company said it is seeing increased market demand for its fuel cell engines.

Ballard Power recently reported its third quarter results, with revenues for the three-month period ended September 30, 2016, totaling $20.6 million, compared to $16.0 million for the same period of the prior year. For the nine months ended September 30, 2016, revenues were $54.6 million, versus $36.5 million the prior year. Shares of Ballard were trading at $1.91 on the Nasdaq Global Market as of January 17, 2017.

Last month, Ballard announced that its stock ticker symbol on the Toronto Stock Exchange (TSX) had been changed to BLDP. The result is that the company now has the same ticker symbol on both the Nasdaq and TSX.

Ballard was named one of the nation’s Top 20 innovative public technology companies by the Canadian Innovation Exchange (CIX).

For more information, please visit www.Ballard.com

Leading health care information technology company Medical Transcription Billing, Corp. (NASDAQ: MTBC; MTBCP) this morning issued a news release recapping its corporate accomplishments for 2016, as well as its objectives for the coming months. Among last year’s highlights, MTBC continued to employ a tactical acquisition-based growth strategy, added important new clients in major markets across the country, recorded strong financial results and earned numerous prestigious accolades for its innovative health care information technology solutions.

In an effort to rapidly expand its client base, MTBC completed four vital acquisitions in 2016, including the purchase of Texas-based medical billing company MediGain, LLC. Completed in October, the MediGain acquisition marked MTBC’s largest acquisition to date. The company’s management team forecasts that incremental profits from this transaction will significantly exceed the cost of capital, with the MediGain transaction expected to be accretive to MTBC shareholders during fiscal 2017.

MTBC’s 2016 growth strategy wasn’t limited to acquisitions, however. The company also recorded strong organic growth, adding an impressive 76 new clients over the course of the year, including 35 new clients in the fourth quarter alone. When fully deployed, MTBC’s fourth quarter client additions are expected to generate more than $1 million of annual revenue, which would mark a record quarter in terms of sales activity for the Software-as-a-Service (SaaS) provider. Notably, MTBC also made efforts to reward its most loyal customers through the introduction of a unique Client Loyalty Program. Through this first-of-its-kind program, the company aims to recognize all the physicians, practices and health organizations who contribute to MTBC’s sustained success.

“We greatly value our clients and their support of our corporate endeavors to facilitate affordable, quality healthcare,” Stephen Snyder, president of MTBC, added in this morning’s update. “We are the first healthcare IT company to offer a loyalty program of this nature, and the positive feedback we have received thus far validates client confidence in our model, services and company.”

These initiatives, in addition to the introduction of a number of new products to the market and strategic efforts to reduce overall general and administrative expenditures, helped MTBC build on its recent fiscal performance throughout 2016. The company reported four consecutive quarters of positive Adjusted EBITDA from the fourth quarter of 2015 to the third quarter of 2016, and Chief Financial Officer Bill Korn notes that MTBC is strategically positioned to “continue this growth trend” in 2017.

Looking forward, MTBC has set a number of objectives for the coming months designed to build on its momentum from 2016. These include the launch of inventive, disruptive products that will help its clients navigate the ever-changing federal health care requirements. A few of the products that are already set for launch in the first quarter include “a comprehensive Accountable Care Organizations (ACO) analytics platform; a reinvented new Electronic Health Record platform; and a solution to efficiently and effectively manage and maintain enrollments for carriers, benefit administrators and groups.”

“We had several impactful and defining achievements in 2016, and we expect to maintain this pace in the upcoming year,” concluded Snyder. “We will continue investing in new product developments that are expected to be accretive to shareholders in 2017 and years to come, and our company looks forward to building on the success we have created.”

For more information, visit www.MTBC.com

Although 28 states have already legalized marijuana for medicinal or recreational use, the U.S. Drug Enforcement Administration (DEA) continues to label marijuana a Schedule 1 substance, along with heroin and LSD, making it illegal on a federal level. As a result, the banking industry has been slow to provide services to marijuana businesses, forcing many of these companies to operate on a cash-only basis. A “bankable” marijuana industry, however, would have widespread implications, including for companies like Singlepoint, Inc. (OTC: SING), Terra Tech Corp. (OTCQX: TRTC), OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ChineseInvestors.com, Inc. (OTCQB: CIIX).

Cash transaction businesses are a tempting target for thieves, and the lack of oversight at times leads to lost tax revenue. It’s a situation that Senator Elizabeth Warren, a member of the Senate Banking Committee, is anxious to change. As the Associated Press initially reported, Warren and nine other senators have called upon the Financial Crimes Enforcement Network to issue new and stronger guidance allowing banks to provide services to marijuana shop vendors. The moves are a significant encouragement to payment processors supporting the cannabis industry, as well as other industry players.

One of the supporters is Singlepoint, Inc. (OTC: SING), a mobile technology and payments provider, which, through its “SingleSeed” Payments subsidiary, provides payment solutions for the cannabis industry. Its mobile marketing and payment solutions include cashless ATM, Pay-by-Text™ and text message marketing. The company is strongly encouraged by the efforts of Senator Warren and others on Capitol Hill, and the significant positive changes they could bring.

Another company that stands to gain with this new market opportunity is ChineseInvestors.com, Inc. (CIIX). ChineseInvestors.com, a company that provides investor information to the global Chinese community, and also offers a unique link to this community for growing businesses. The company recently announced plans to launch the “world’s first Cannabidiol (CBD) health products online store in the Chinese language,” through an agreement with a “well-known” CBD health brand.

Other cannabis-related companies in line to benefit from mounting support of a bankable marijuana industry include Terra Tech Corp. (TRTC). Through its subsidiaries, Terra Tech provides a range of hydroponic equipment for indoor cultivation of cannabis products. In addition, the company sells hydroponic cannabis produce and associated products. Another is OWC Pharmaceutical Research Corp. (OWCP), an Israeli company that develops cannabis products for the treatment of diseases, also offering consulting services in the industry.

Previous guidance efforts by the U.S. Department of the Treasury gave banks only limited permission to work with legal marijuana businesses. Along with the DEA’s Schedule 1 listing, it has created a significant gap between state and federal treatment of marijuana. Even though the number of financial institutions willing to provide services to marijuana businesses has grown significantly in recent years, only a small percentage currently serve the industry. It’s still an area dominated by small state-chartered banks and credit unions.

Supporters however see an inevitable day, through efforts such as those now being led by Senator Warren, when large national banks like Wells Fargo offer comprehensive services to the cannabis industry, further spurring already rapid industry growth.

For more information, please visit: Singlepoint, Inc. (SING)

Let us hear your thoughts: Singlepoint, Inc. Message Board

HIV/AIDS may not be as much in the news as it was back in the 1980s, but the disease has not gone away. According to the Centers for Disease Control and Prevention (CDC) (http://nnw.fm/7yEVU), it still affects ‘more than 1.2 million people in the US… and 1 in 8 of them don’t know it’.

Although, perennially lumped together, HIV and AIDS are not synonymous. Not all those infected with HIV (HIV positive) have AIDS (acquired immunodeficiency syndrome), which is the final stage of HIV infection. The goal of antiretroviral therapy or ART has been to stop that progression. And that is what PRO 140 from CytoDyn Inc. (OTCQB: CYDY) hopes to do. By minimizing the HIV viral load, PRO 140 could prevent HIV from turning into AIDS.

Viral load (VL), the number of virus (HIV) particles per milliliter of blood, is an important biomarker in the fight against HIV/AIDS. The lower the viral load, the less chance there is that an HIV-infected person will develop AIDS. And although, a viral load of less than 200 copies per milliliter of blood is considered a low level of viral suppression, the therapeutic goal is an ‘undetectable’ VL of 50 or less.

Viral load also affects HIV transmission. The greater the viral load, the greater the risk of transmitting the virus. However, effective antiretroviral therapy can reduce viral load (VL) considerably and thus the transmission of HIV by more than 96 percent. A VL of less than 40 copies per milliliter of blood reduces the transmission rate practically to zero.

For some of those who, like Charlie Sheen, are participating in the current Phase III clinical trials for PRO 140, this level of viral load has already been achieved. A December story in the U.K. Daily Mail (http://nnw.fm/l0Kn9) quoted the actor as saying he had been able to achieve an undetectable viral load by taking PRO 140.

Sheen, who disclosed in late 2015 that he had tested HIV positive some four years earlier, has been part of the PRO 140 trials for about nine months.

He waxed eloquently on an ABC News (http://nnw.fm/rSx4d) interview about the hope brought into his life by using PRO 140: “I can feel the future with this thing and it’s much bigger and more important than I am”. The 51-year-old actor says he feels like he is carrying the torch for fellow sufferers of HIV/AIDS. Adding, “We are very close to being approved”.

Last Wednesday, CytoDyn announced (http://nnw.fm/ETlo9) it had filed a request with the FDA for Breakthrough Therapy Designation for PRO 140 as a treatment for HIV-1 infection in treatment-experienced patients with virologic failure. The company believes PRO 140 will be useful in caring for ‘heavily treatment-experienced HIV patients’ who have developed drug resistance to their current treatments. In contrast to the current highly active antiretroviral therapy (HAART), which is typically a ‘cocktail’ of drugs, PRO 140 works alone.

The ongoing clinical trials have yielded promising results. For approximately 24 months, enrolled patients showed no drug resistance and viral load suppression was maintained for the same period. There was no impact on the immune function nor were there any serious adverse events. Additionally, to date, there have been no serious side effects in the over 200 patients.

CytoDyn management is, understandably, excited at the progress. Dr. Nader Pourhassan, CytoDyn’s President and CEO, has said,

“We believe PRO 140 has demonstrated its value as a combination therapy and as a single agent in patients with the R5 strain of HIV and are hopeful that receiving Breakthrough Therapy Designation will speed our BLA (biologic license application) process to get this product to the market.”

The U.S. market size for HIV therapies is estimated at around $15 billion.

For more information, visit www.Cytodyn.com

Moxian, Inc. (NASDAQ: MOXC) is positioning itself as a leader in China’s O2O services market as the sector enjoys a 20% surge in year-over-year growth. iResearch Consulting Group, in its ‘2015 China Online-to-Offline (O2O) Services Model Research Report’ published in January 2016 (www.iresearchchina.com), stated that the Chinese O2O market was on course to grow from $53.78 billion in 2015, to $68.71 billion in 2016. The report also forecast growth of 20% year-over-year through 2018 to more than $90 billion (http://nnw.fm/Jyj1C).

The reason for the quick growth is a high level of usage of the online services sector. Tencent Penguin Intelligence’s ‘2015-2016 Report on the Year’s Internet Trends in China’ noted that online-to-offline services were purchased by more than three-quarters of Chinese internet users between 20-40 years of age. Women were responsible for more than half of the O2O purchases, such as food delivery services and travel bookings. The report also found that higher educated consumers used the services more often, with more than 80% of respondents who made an O2O purchase having a bachelor’s degree.

The growth of O2O in China might also be attributed to relatively low levels of auto ownership, as compared to the U.S. As a result, delivery services to the home are particularly attractive. The O2O sector represents a click-and-collect market of services that can be ordered online, then paid for at point-of-service, eMarketer reports.

According to an April 2016 report on Chinese digital consumers from McKinsey (http://nnw.fm/XhMG3), half of the digital consumers surveyed use social media to view products or get recommendations, and 31% of the WeChat consumers it surveyed actually made a purchase on that platform — double the figure from the year before. Impulse purchases are driven by social media, particularly in categories such as personal care and apparel. McKinsey also reported that O2O’s convenience and discount expectations were stimulating greater online spending in China.

In its survey of 3,100 online users in China, titled ‘How Savvy, Social Shoppers Are Transforming Chinese E-Commerce’, McKinsey found that the future of commerce and O2O service has tremendous potential. Future growth, it states, will be near term. Mobile devices are used to access the internet across China. McKinsey found that, after buying travel services from O2O vendors, 77% of consumers surveyed said their total spending on travel increased. Furthermore, 65% of consumers spent more after using other O2O services. They spent it on dining and increased mobility, the report stated. “This suggests that O2O services offering a unique value proposition could power additional growth in China’s online market over the years to come,” McKinsey analysts noted.

Finally, the report observed that vendors serving the rapidly expanding O2O markets have attracted huge sums of capital from investors as the next big thing in digital China. Moxian, Inc., did just that when it raised $10 million in new capital in 2016 through a public offering of its common stock. Moxian traded at $3.25 per share as of January 17, 2017.

The company’s headquarters are in Shenzhen, China, and it also has an office in Beijing. In addition, it reported to the SEC in its 10-K for the fiscal year ended September 30, 2016, that it is expanding, with offices planned for Shanghai and Guangzhou. What Moxian says makes it unique is that it signs up merchants initially, then builds its user base from their customers.

For more information, visit www.Moxian.com

At one time there was a feeling that, in an age where virtually everything is connected and platforms such as Skype and Facetime make video conferencing easily accessible, traveling for business would no longer be necessary. However, according to Globetouch (http://dtn.fm/rsN9l), the Asia-Pacific region doubled its business travel output between 2005 and 2015, with these numbers expected to grow further during the coming years.

This has been attributed, in part, to the fact that more people are learning how to combine business travel with leisure, encouraging many to look upon business travel as a positive. According to ‘Predictions: The 8 Hot Travel Trends In 2017’ (http://dtn.fm/6Igkt), a WIT article, “30% of travelers said they would accept a lower paid job if it meant they could travel more for work.” It also states that “Of the 40% of global travelers who journeyed for business this year, 46% would travel even more for business in 2017.”

Businessmen and women are realizing that it is possible to combine work and pleasure, and opting to travel more for work makes the leisure opportunities more affordable. With many business travelers today being millennials, they expect a seamless travel experience, where they can see to their business affairs while incorporating some rest and relaxation into their trips. With the help of technology, this has been made possible.

Monaker Group, Inc. (OTCQB: MKGI), a technology driven travel company with a number of divisions and brands boasting more than 60 years of combined experience in the travel and leisure industry, provides an all-in-one platform through its flagship NextTrip.com planner, which makes planning work and leisure combination travel easy.

The NextTrip.com travel planner works with a range of mobile devices, and it allows those traveling for both business and pleasure to organize and plan a trip from start to finish. Including rental homes, hotels, timeshare resorts, airlines, tours, and car rentals, the travel planner makes the multitude of options clear to the user on one screen. In addition to the above, the planner gives users the chance to import all bookings onto one device; find attractions, restaurants, and bars in their desired locations; and maintain a level of financial organization, all for free.

For more information, visit www.MonakerGroup.com

Once New York-based Axsome Therapeutics, Inc. (NASDAQ: AXSM) was founded in 2012, its team set out to establish a fully-integrated biopharmaceutical business that would develop therapies to treat and manage central nervous system (CNS) disorders. Now in 2017, the Axsome team is setting off on another exciting leg on this journey.

For years, Axsome has been laser-focused on improving the lives of patients living with pain and various CNS disorders. With an eye toward differentiated therapies, the company has concentrated on developing and commercializing both in-licensed drug candidates and internally-derived drug candidates in order to accomplish its goal of increasing the treatment options accessible to caregivers.

Along the way, industry analysts have pointed out the value in Axsome’s focus on complex regional pain syndrome, treatment resistant depression and agitation in patients with Alzheimer’s disease (AD); the lower-than-average research and development risks, as well as the tested business models that surround these disorders, hint at a faster commercialization schedule.

During the first week of 2017, a new report from AEGIS Capital Corp. (http://dtn.fm/w6MIe) also alluded to Axsome’s accelerated timeline and other investment highlights, including recent developments affecting one of the company’s two late-stage drug candidates: AXS-05, a fixed-dose combination of dextromethorphan and bupropion that is being developed for multiple indications, including treatment resistant depression and agitation in patients with AD.

According to the AEGIS report, on January 4, 2017, Axsome announced that the United States’ Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application for a phase II/III clinical trial of AXS-05 in AD. This is a significant development for the company, as this IND program is the means by which a pharmaceutical company operating within the United States obtains permission to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved. With the FDA’s approval in tow, the placebo-controlled, randomized, double-blind, multicenter trial is now set to register the necessary 330 patients and to commence sometime in the first half of 2017.

To learn more, visit www.Axsome.com

National Waste Management Holdings, Inc. (OTC: NWMH) has turned the old aphorism ‘garbage in – garbage out’ on its head. It’s now ‘garbage in, revenues up’. In its last 10-Q filing, for the third quarter ended September 30, 2016, the company reported quarterly revenues of $1.8 million, which represented a 269 percent increase over 2015 same period revenues. This stellar performance in the third quarter boosted revenues in the nine-month period ended September 30, 2016, to $4.9 million, up by 262 percent over same period revenues for 2015. Not all garbage, it seems, is waste.

National Waste operates a licensed 54-acre landfill in Hernando, Florida, that disposes of roughly 240,000 cubic yards of construction debris annually. These landfill services include the disposal of asphalt and rock; lumber and wood; brick; wallboard, drywall and plaster; pallets; rock concrete; dirt, sand and uncontaminated soil; plumbing fixtures; non-asbestos insulation; roofing materials and shingles; glass; piping; waste metal; brush and land clearing; yard and tree waste; and many electrical and wiring components.

However, as extensive as those facilities are, they do not encompass the whole range of landfill services. There’s a lot more to garbage disposal than meets the eye.

Solid waste, defined as household garbage and industrial non-hazardous waste, is disposed of in a variety of landfills. Municipal solid waste landfills (MSWLF) are designed to accommodate the disposal of household waste but may accept other types of non-hazardous wastes, such as commercial solid waste, non-hazardous sludge, and industrial non-hazardous solid waste. A special kind of MSWLF is the bioreactor landfill, designed to degrade waste in a controlled manner.

Even though some commercial solid waste and industrial non-hazardous solid waste ends up in MSWLFs, there are special facilities, known as industrial waste landfills, designed to take commercial and institutional waste. In this category are construction and demolition (C&D) debris landfills, designed exclusively for construction and demolition materials, which consist of the debris generated during the construction, renovation and demolition of buildings, roads and bridges. C&D materials are typically bulky, heavy materials, such as concrete, wood, metals, glass and salvaged building components.

Another type of industrial waste landfill is the coal combustion residual (CCR) landfill, which is meant to accommodate coal ash and other residuals from coal combustion.

With such a heterogeneous landscape, there is ample opportunity for National Waste to continue the implementation of its vertical integration strategy. Apart from its landfill services, the company rents out roll-off containers of 20, 30 and 40 cubic yard capacity. It also offers recycled wood mulch and garden mulch products. The route is clear for National Waste to realize its long-term goal of servicing the entire East Coast, from Florida to New York.

National Waste is a vertically-integrated waste management company offering landfill, transfer station, garbage collection and container services for both commercial entities and residential customers in Central Florida and Upstate New York. The company presently services the counties of Citrus, Hernando, and Marion in Florida and Upstate New York with 13 roll-off trucks and approximately 800 containers.

For more information, visit the company’s website at www.nationalwastemgmt.com

Let us hear your thoughts: National Waste Management Holdings, Inc. Message Board

Lomiko Metals (OTCQB: LMRMD) (OTC: LMRMF) has positioned itself on top of an extremely positive supply-demand curve, with a unique opportunity for low-cost production of a key mineral that underpins much of the growing green economy.

Lomiko’s core focus is on the exploration and development of minerals such as lithium and graphite, the latter of which is used for energy storage in products such as lithium-ion batteries, especially those used for electric vehicles (EV), and for which there is no cheaper alternative.

The demand for EVs is expected to see rapid growth for at least the next 20 years, and the demand for flake graphite is forecast to exceed the supply by 2018. For perspective, if Tesla’s (NASDAQ: TSLA) Gigafactory meets its proposed rate of 500,000 cars per year by 2020, this facility alone would require the entire supply of lithium-ion batteries available today. Tesla plans on meeting its own supply, however, and upon full capacity – expected by 2018 – the Gigafactory is expected to produce more batteries each year than the total produced worldwide in 2013.

Lomiko’s exceptional position in all this is the fact that it has acquired a superior graphite mining property in Quebec, the La Loutre Flake Graphite Property. The property’s verified quality-grade mineralization is close to the surface, which reduces costs, and it is also close to the port of Montreal for easy shipment.

As of now, China controls about 70% of the world’s graphite, only a portion of which is the desirable flake graphite. High-purity crystal flake graphite supply is especially limited and the center of demand, since it is the form of graphite needed for lithium-ion batteries and other green technologies. As demand for graphite threatens to overtake supply, companies like Lomiko with productive flake graphite properties will be in an especially commanding position.

Another reason graphite demand continues to rise is that when the mineral is processed into graphene it becomes an almost science fiction-like material, with properties that offer untold possibilities.

Graphene is the world’s first two-dimensional material, meaning that it is made from sheets of connected carbon atoms just one atom thick, but of unlimited width and breadth. It is a thousand times as conductive as copper, even at room temperature; extremely light and flexible, yet 200 times stronger than steel; and, though it is a new material, thousands of patents have already been filed relating to it, including 3D printing, where Lomiko holds an equity position with a 3D printing lab.

Graphene’s huge potential for application, in green technologies and other areas, is the reason Lomiko plans to create joint ventures through its subsidiary, Lomiko Technologies, an investor in graphene technology and manufacturer of electronic products. The company has already developed a partnership with Graphene Laboratories Inc., a Graphene 3D Lab, Inc. (OTCQB: GPHBF) company, for the development of a process whereby graphite can be efficiently converted into graphene.

Fully supporting the push for a new green economy, and driven by a highly-qualified management team with foresight into industry demand, Canada-based Lomiko is well-positioned as an active, competitive player in the broader mining and minerals sector.

For more information, visit www.Lomiko.com

A growing number of health care professionals and medical practices are resorting to electronic management technologies, ranging from electronic health records to revenue cycle management, practice management and scheduling software and more. As a leading provider of integrated health care technologies, New Jersey-based Medical Transcription Billing, Corp. (NASDAQ: MTBC; MTBCP) is leveraging its proprietary technology to serve a wide range of health care customers across 40+ states, currently offering one of the most comprehensive suites of practice management, electronic health records and revenue cycle solutions on the market.

Already serving hundreds of customers, the company traditionally recognizes the efforts of client practices that make the best use of the MTBC platform, on both a monthly and annual basis. Earlier this month, MTBC announced that the ‘Office Manager of The Year’ award for 2016 was going to a Maryland-based family practice that has been using the company’s integrated billing services, practice management and electronic health records software for three years. The winner, Baqar Naqvi from Progressive Medical Care, LLC, has consistently secured an ‘Excellent’ rating for his practice’s use of MTBC technologies, according to a company press release (http://nnw.fm/VS1lR).

Under Naqvi’s management and with the help of MTBC’s software, Progressive Medical Care reported a 100 percent increase in its collections. Other best practices he implemented include the exclusive electronic generation of claims, making sure that all providers were using MTBC patient engagement software and ensuring that all tests were ordered via the integrated LAB interface.

As recipient of the ‘Office Manager of the Year’ award, Naqvi will receive a cash bonus of $1,000 and other incentives. MTBC Division President Loraine Goetsch also congratulated the winner and underlined that, due to dedicated practice managers such as Naqvi, Medical Transcription Billing has been able to successfully and continually develop and evolve its platforms with new and innovative features.

Every month, Medical Transcription Billing recognizes the efforts of practice managers who make sure that their offices make the best and most efficient use of WebEHR and practice management tools provided by MTBC. At the end of the year, the company uses the same criteria to pick the Office Manager of the Year based on each practice’s score and how effectively it used its integrated technologies. MTBC has so far recognized the dedication of more than 150 office managers.

Founded in 1999, MTBC provides a fully-integrated suite of web-based health care information technology solutions and related business services. Its integrated technologies have four core components: Electronic Health Records – allowing physicians to create and review patient charts online; Practice Management – automating labor-intensive medical offices’ workflow in a streamlined platform; Revenue Cycle Management – improving the medical reimbursement process and increasing collections; and mHealth – extending the core components of the platform to the mobile environment.

Built around the company’s proprietary ChartsPro™ software, the EHR system is easy to use and intuitive, being designed to improve the productivity of any practice by automating all of its clinical activities. The system includes 13 specialty-specific modules, including Internal Medicine, Family Medicine, Podiatry, OB/GYN, Pediatrics, Psychiatry and Rheumatology.

Other top features of the MTBC software include Patient Charts, allowing for the storage of extensive patient information such as vitals, social history and care plan; a Clinical Decision Support System, which helps provide preventative care with evidence-based alerts; and a Personal Tab module, which enables detailed documentation of patient demographics.

For more information, visit www.mtbc.com, and see the company’s fact sheet at http://ir.mtbc.com/events.cfm